ROCHESTER, Mich., May 09, 2016 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (OTCQB:OPRX), a health technology software company whose premier content-delivery platform enables pharmaceutical companies to provide on-demand patient-care services, reported results for the first quarter ended March 31, 2016.

Q1 2016 Highlights

  • Promotional transactions, including eCoupons and eVouchers, up 16% in the quarter.
  • Net revenue up 18% to $1.8 million in the quarter.
  • eCoupons distributed for 73 different brands in the quarter, up from 57 brands in the first quarter of 2015.
  • Partnered with TrialCard to integrate its coupon and co-pay offerings with OptimizeRx electronic health record (EHR) technology.
  • Sponsored the ePrescribe/EHR conference held in Philadelphia in March, which generated significant leads for the company’s sales force.
  • Appointed William J. Febbo as CEO. Febbo brings to OptimizeRx more than 18 years of experience in building and managing health services and financial businesses.
  • Appointed James Brooks as SVP of business development. Brooks brings more than 20 years of experience in sales and marketing. 
  • Added sales rep on the East Coast.

Q1 2016 Financial Summary
Net revenue in the first quarter of 2016 was $1.8 million versus $1.5 million in the same year-ago quarter. The increase was due to both increased promotion of pharmaceutical brands and expanded distribution channels.

Operating expenses in the first quarter of 2016 were $1.2 million, as compared to $0.8 million in the same year-ago quarter. The increase was primarily due to an increase in expenses related to growth initiatives, including investments in the company’s executive and sales team and related marketing and travel. Since the first quarter of 2015, the company has appointed a vice president of client services, a senior vice president of business development, an additional vice president of sales, and a CEO.

Net loss was $352,000 or $(0.01) per share, as compared to net loss of $111,000 or $(0.00) per share in the same year-ago quarter.

Cash and cash equivalents totaled $7.5 million at March 31, 2016, as compared to $8.2 million at December 31, 2015. The decrease in cash and equivalents was due to the payout to the company’s former CEO for shares owed to him from prior years, in lieu of actually issuing those shares. Without that payout, the company’s cash would have increased slightly during the quarter. The company continued to operate debt-free.

Management Commentary
“OptimizeRx has generated 16 consecutive quarters of year-over-year sales growth, driven by acquiring, integrating and expanding into new promotional EHR and eRx platforms,” said William Febbo, OptimizeRx’s CEO. “Currently, our focus is on building out our internal team to expand our reach within EHR providers, pharmacies and consumers. This team will leverage our existing client engagements to drive continued top-line growth. As a first mover and developer of the eCoupon market, we are aggressively expanding our suite of products and services designed to efficiently maximize the marketing channel for our clients.”

“Looking ahead, we will continue to invest in expanding our team to scale our business. We will also invest in technology and marketing while delivering a consistent message to potential customers that we connect fragmented EHR channels with our ‘single point of access’ promotional network.”

Conference Call
OptimizeRx will host a conference call today to discuss the first quarter 2016, followed by a question and answer period.

Date: Monday, May 9, 2016
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Toll-free dial-in number: 1-877-397-0272
International dial-in number: 1-719-325-4749
Conference ID: 2574067

A replay of the call will be available through May 30, 2016.

Toll-free replay number: 1-877-870-5176
International replay number: 1-858-384-5517
Replay ID: 2574067

The company expects to file its quarterly report on Form 10-Q today.

About OptimizeRx Corp
OptimizeRx Corporation (OTCQB:OPRX) provides unique consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to expand awareness, access and adherence to their medications.

The company’s core product, SampleMD, replaces drug samples with electronic trial vouchers and copay coupon savings that are electronically added to an e-Prescription and sent electronically to the pharmacy and is integrated within leading electronic health record (EHR) platforms in the country, including Allscripts, Quest Diagnostics, Practice Fusion and over 350 other EHRs to reach over 250,000 healthcare providers. In turn, OptimizeRx promotes patient savings and support from the world’s largest pharmaceutical companies, including Pfizer, Lilly, Novartis, AstraZeneca and many others. For more information, please go to www.optimizerxcorp.com.

Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

 
OPTIMIZERx CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED)
AS OF MARCH 31, 2016 AND DECEMBER 31, 2015
     
  March 31, 2016 December 31, 2015
ASSETS    
Current Assets        
Cash and cash equivalents $7,548,261  $8,207,565 
Accounts receivable  2,340,765   2,847,450 
Prepaid expenses  54,555   70,623 
Total Current Assets  9,943,581   11,125,638 
Property and equipment, net  23,076   10,239 
Other Assets        
Patent rights, net  817,239   832,884 
Web development costs, net  308,812   340,470 
Security deposit  5,049   5,049 
Total Other Assets  1,131,100   1,178,403 
TOTAL ASSETS $11,097,757  $12,314,280 
         
LIABILITIES AND STOCKHOLDERS' EQUITY        
Current Liabilities        
Accounts payable - trade $195,076  $212,191 
Accounts payable - related party  -   570,000 
Accrued expenses  8,090   6,983 
Revenue share payable  1,502,816   2,355,608 
Deferred revenue  845,226   227,002 
Total Liabilities  2,551,208   3,371,784 
Stockholders' Equity        
Common stock, $.001 par value, 500,000,000 shares authorized, 29,043,425 and 29,030,925 shares issued and outstanding, respectively  29,043   29,031 
Preferred stock, $.001 par value, 10,000,000 shares authorized, 0 and 65 shares issued and outstanding, respectively  -   - 
Stock warrants  2,294,416   2,329,508 
Additional paid-in-capital  32,631,226   32,185,499 
Stock payable  663,670   1,132,148 
Deferred stock compensation  -   (13,800)
Accumulated deficit  (27,071,806)  (26,719,890)
Total Stockholders' Equity  8,546,549   8,942,496 
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $11,097,757  $12,314,280 
         


OPTIMIZERx CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)
FOR THE THREE MONTHS ENDED MARCH 31, 2016 AND 2015
   
  For the Three Months Ended
  March 31
    2016    2015 
       
NET REVENUE $ 1,759,528  $ 1,487,553 
       
COST OF SALES   892,793    756,440 
       
GROSS MARGIN   866,735    731,113 
       
OPERATING EXPENSES   1,228,564    842,610 
       
LOSS FROM OPERATIONS   (361,829)   (111,497)
       
OTHER INCOME (EXPENSE)      
Interest income   10,076    296 
Interest Expense   (163)   - 
       
TOTAL OTHER INCOME (EXPENSE)   9,913    296 
       
LOSS BEFORE PROVISION      
FOR INCOME TAXES   (351,916)   (111,201)
       
PROVISION FOR INCOME TAXES   -    - 
       
NET LOSS $ (351,916) $ (111,201)
       
WEIGHTED AVERAGE SHARES OUTSTANDING 
   
BASIC AND DILUTED   29,030,925    22,897,819 
       
NET LOSS PER SHARE      
       
BASIC AND DILUTED $ (0.01) $ (0.00)
       

Company Contact:
OptimizeRx
Doug Baker
dbaker@samplemd.com
248-651-6568 x807 

Investor Relations Contact:
Liolios Group
Ron Both, Senior Managing Director
oprx@liolios.com 
949-574-3860

Primary Logo